Disclosed is a nanocomplex, a preparation method therefor, and a use thereof. The nanocomplex comprises 0-60% a protein drug, 0.03-15% hyaluronic acid, 0.8-20% protamine, 35-95% lipid components, and 2.5-40% a apolipoprotein and/or a mimetic peptide thereof; the lipid components comprise an electrically neutral lipid and an anionic lipid; and the total amount of hyaluronic acid and protamine is 0.03-15%. The nanocomplex of the present invention provides a general-type carrier for protein drugs having different physicochemical properties (such as molecular weights of 10-255 KDa and PIs of 4-11), implements highly efficient intracellular, in vivo, and even in-brain delivery, utilized technology is universal in nature, and said invention can effectively solve the current problem of insufficient in vivo and in vitro transport of protein drugs (comprising a protein drug exceeding the molecular weight and PI of an embodiment).

The present disclosure relates to erythroid cells that have been engineered to comprise a uricase, a uric acid transporter, or both a uricase and a uric acid transporter. The engineered erythroid cells of the present disclosure are useful in degrading uric acid inside the engineered erythroid cell. The engineered erythroid cells of the present disclosure are useful in methods of treating hyperuricemia. The engineered erythroid cells of the present disclosure are also useful in methods of treating gout, and in particular chronic refractory gout.

The present invention relates to compositions comprising a polymeric matrix or a gel containing functional enzymes capable of re-creating under culture conditions the cell microenvironment existing in vivo. The present invention also relates to devices for cell cultures comprising such compositions, in particular hydrogel and the use thereof to control the chemical microenvironment of a cell culture or mimic physiological or pathological conditions of the in vivo cells. The compositions and the devices described herein could be also used in vitro for evaluating the therapeutic effect of a compound on a determined cell line or on primary cells.

The present invention relates to biocatalytic methods, comprising purely enzymatic, mixed enzymatic-fermentative and purely fermentative methods, for the direct single-step conversion of L-fucitol to L-fucose, in order to easily obtain L-fucose at high amounts and levels of purity. Suitable recombinant microorganisms and fungi are further disclosed and also the use thereof in said method for the single-step conversion to L-fucose.

Provided are a filamentous fungus mutant strain having an effect of improving C4 dicarboxylic acid productivity, and a method for producing C4 dicarboxylic acid using the filamentous fungus mutant strain. The method for producing a C4 dicarboxylic acid comprises culturing a filamentous fungus mutant strain which has enhanced expression of a polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 2 or an amino acid sequence having at least 90% identity thereto and having catalase activity is enhanced.

Enzyme compositions including lactate responsive enzyme and stabilizing agent, including electrodes, sensors, and systems having the same. The stabilizing agent stabilizes the lactate responsive enzyme in a manner sufficient to increase sensitivity to lactate, such as for use in in vivo detection of lactate. In some compositions the lactate responsive enzyme is lactate oxidase and the sensor includes a heterocycle-containing polymer and a crosslinker.

Agents, kits, and methods that utilize oxygenation to treat Inflammatory Bowel Disease (IBD) and/or provide prophylaxis against exacerbation of IBD are provided. In several embodiments, the agents, kits, and methods according to several embodiments generate in, or carry to, oxygen in the intestinal lumen to treat IBD and provide prophylaxis against exacerbation of IBD, including those caused by the presence of anaerobic bacteria in the intestine. The agents, kits, and methods provided herein generate an aerobic environment within the intestine to alleviate intestinal inflammation.

The inventive technology relates to systems and methods for enhanced in vivo production, accumulation and modification of cannabinoids. In one embodiment, the invention may include systems and methods for enhanced in vivo biosynthesis of chemically-modified water-soluble cannabinoids in a whole plant, or a cell suspension culture system.

Isolated oxidases, isolated polynucleotides encoding the oxidases, and methods of using the oxidases to produce -oxocarboxylic acid compounds or L--amino acid compounds are described.

The present invention relates to enzyme compositions and processes of producing and using the compositions for the saccharification of lignocellulosic material.